Drug therapy of hypercholesterolaemia in children and adolescents

Drugs

Volumn 72, Issue 6, 2012, Pages 759-772

  Braamskamp, Marjet J A M ^a   Wijburg, Frits A ^a   Wiegman, Albert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adolescents; Atherosclerosis; Bile acid binding protein modulators; Cardiovascular disorders; Children; Cholesterol ester transfer protein inhibitors; Ezetimibe; Fibric acid derivatives; HMG CoA reductase inhibitors; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Microsomal triglyceride transfer protein inhibitors; Niacin; Sitosterolaemia; Teratogenesis

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; MIPOMERSEN; NICOTINIC ACID; PHYTOSTEROL; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SITOSTEROL; TOBACCO SMOKE; UNINDEXED DRUG;

ADD ON THERAPY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOSOMAL RECESSIVE DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CLINICAL PRACTICE; CREATINE KINASE BLOOD LEVEL; DIET RESTRICTION; DIETARY FIBER; DIETARY INTAKE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERURICEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER TOXICITY; LOW FAT DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MYOPATHY; NEPHROTIC SYNDROME; OBESITY; ORGAN TRANSPLANTATION; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PROTEINURIA; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SIDE EFFECT; SITOSTEROLEMIA; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84859920295     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11632810-000000000-00000     Document Type: Article

References (98)

1. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998; 338 (23): 1650-6 (Pubitemid 28267909)
2. McGill Jr HC, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women: the PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 1997; 17 (1): 95-106 (Pubitemid 27057330)
3. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation 2010; 122 (24): 2514-20
4. Wiegman A, de GE, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363 (9406): 369-70 (Pubitemid 38169546)
5. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40 (12): 2117-21 (Pubitemid 36005896)
6. Goldstein JL, Hobbs HH, Brown MS. The metabolic and molecular bases of inherited disease. In: Scriver C, Beaudet A, Sly W, et al., editors. Familial hypercholesterolemia. New York: McGraw-Hill, 2001: 2863-913
7. van der Graaf A, Avis HJ, Kusters DM, et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011; 123 (11): 1167-73
8. Abifadel M, VarretM, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34 (2): 154-6 (Pubitemid 36666925)
9. Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31 (8): 1337-49 (Pubitemid 20261898)
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486-97
11. Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49 (3): 476-88
12. Brunzell JD, Schrott HG, Motulsky AG, et al. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976; 25 (3): 313-20
13. Cortner JA, Coates PM, Gallagher PR. Prevalence and expression of familial combined hyperlipidemia in childhood. J Pediatr 1990; 116 (4): 514-9 (Pubitemid 20124144)
14. Lapinleimu J, Nuotio IO, Lapinleimu H, et al. Recognition of familial dyslipidemias in 5-year-old children using the lipid phenotypes of parents: the STRIP project. Atherosclerosis 2002; 160 (2): 417-23 (Pubitemid 34159336)
15. Kuromori Y, Okada T, Iwata F, et al. Familial combined hyperlipidemia (FCHL) in children: the significance of early development of hyperapoB lipoproteinemia, obesity and aging. J Atheroscler Thromb 2002; 9 (6): 314-20
16. Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease: II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52 (7): 1544-68
17. de GJ, Stalenhoef AF. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol 1998; 9 (3): 189-96 (Pubitemid 28274347)
18. Veerkamp MJ, de GJ, Bredie SJ, et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002; 22 (2): 274-82 (Pubitemid 34127039)
19. Veerkamp MJ, de GJ, Stalenhoef AF. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2005; 25 (5): 1026-31 (Pubitemid 40627850)
20. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. AmJ Cardiol 2003; 92 (4A): 27-33J
21. Cohen JC, Kimmel M, Polanski A, et al. Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr Opin Lipidol 2003; 14 (2): 121-7 (Pubitemid 36521181)
22. Filigheddu F, Quagliarini F, Campagna F, et al. Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia. Atherosclerosis 2009; 207 (1): 162-7
23. Arca M, Zuliani G, Wilund K, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002; 359 (9309): 841-7 (Pubitemid 34233756)
24. Rodenburg J, Wiegman A, Vissers MN, et al. A boy with autosomal recessive hypercholesterolaemia. Neth J Med 2004; 62 (3): 89-93 (Pubitemid 39089467)
25. Soutar AK, Naoumova RP. Autosomal recessive hypercholesterolemia. Semin Vasc Med 2004; 4 (3): 241-8 (Pubitemid 40094488)
26. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292 (5520): 1394-8 (Pubitemid 32476229)
27. Tsubakio-Yamamoto K, Nishida M, Nakagawa-Toyama Y, et al. Current therapy for patients with sitosterolemia: effect of ezetimibe on plant sterol metabolism. J Atheroscler Thromb 2010; 17 (9): 891-900
28. Jarvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002; 51 (2): 493-8 (Pubitemid 34764808)
29. Krantz JS, Mack WJ, Hodis HN, et al. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. J Pediatr 2004; 145 (4): 452-7 (Pubitemid 39345979)
30. Kershnar AK, Daniels SR, Imperatore G, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr 2006; 149 (3): 314-9 (Pubitemid 44308425)
31. Guy J, Ogden L, Wadwa RP, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care 2009; 32 (3): 416-20
32. Schwab KO, Doerfer J, Marg W, et al. Characterization of 33 488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors. Pediatr Diabetes 2010; 11 (5): 357-63
33. Edge JA, James T, Shine B. Longitudinal screening of serum lipids in children and adolescents with type 1 diabetes in a UK clinic population. Diabet Med 2008; 25 (8): 942-8
34. Reh CM, Mittelman SD, Wee CP, et al. A longitudinal assessment of lipids in youth with type 1 diabetes. Pediatr Diabetes 2011; 12 (4 Pt 2): 365-71
35. McMahan CA, Gidding SS, Malcom GT, et al. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 2006; 118 (4): 1447-55 (Pubitemid 46393790)
36. Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007; 357 (23): 2329-37 (Pubitemid 350223387)
37. Franks PW, Hanson RL, Knowler WC, et al. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 2010; 362 (6): 485-93
38. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366 (9491): 1059-62 (Pubitemid 41338752)
39. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365 (9468): 1415-28 (Pubitemid 40523737)
40. Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24 (2): e13-8
41. Huang J, Parish R, Mansi I, et al. Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. J Investig Med 2008; 56 (7): 931-6
42. Zimmet P, Alberti G, Kaufman F, et al. The metabolic syndrome in children and adolescents. Lancet 2007; 369 (9579): 2059-61 (Pubitemid 46935928)
43. Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents: an IDF consensus report. Pediatr Diabetes 2007; 8 (5): 299-306 (Pubitemid 47422902)
44. Morrison JA, Friedman LA, Wang P, et al. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr 2008; 152 (2): 201-6
45. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365 (20): 1876-85
46. Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 2002; 14 (2): 197-204 (Pubitemid 34412164)
47. Prescott Jr WA, Streetman DA, Streetman DS. The potential role ofHMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 2004; 38 (12): 2105-14 (Pubitemid 40169383)
48. Hu P, Lu L, Hu B, et al. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome. Scand J Clin Lab Invest 2009; 69 (6): 680-6
49. Groothoff JW, Lilien MR, van de Kar NC, et al. Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol 2005; 20 (3): 374-9 (Pubitemid 40309946)
50. Litwin M, Grenda R, Prokurat S, et al. Patient survival and causes of death on hemodialysis and peritoneal dialysis: single-center study. Pediatr Nephrol 2001; 16 (12): 996-1001 (Pubitemid 34026710)
51. Bakiler AR, Yavascan O, Harputluoglu N, et al. Evaluation of aortic stiffness in children with chronic renal failure. Pediatr Nephrol 2007; 22 (11): 1911-9 (Pubitemid 47506232)
52. Groothoff JW, Gruppen MP, Offringa M, et al. Increased arterial stiffness in young adults with end-stage renal disease since childhood. J Am Soc Nephrol 2002; 13 (12): 2953-61 (Pubitemid 35386914)
53. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114 (24): 2710-38
54. Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 (5): 2740-6 (Pubitemid 40686318)
55. Wild RA, Rizzo M, Clifton S, et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95 (3): 1073-9
56. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant 2004; 23 (3): 317-22 (Pubitemid 38333089)
57. Chin C, Rosenthal D, Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 2000; 4 (3): 193-9 (Pubitemid 30471308)
58. Sarkissian T, Beyene J, Feldman B, et al. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 2007; 56 (2): 631-8
59. Ardoin SP, Sandborg C, Schanberg LE. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007; 16 (8): 618-26 (Pubitemid 47359998)
60. Ilowite NT, Samuel P, Beseler L, et al. Dyslipoproteinemia in juvenile rheumatoid arthritis. J Pediatr 1989; 114 (5): 823-6 (Pubitemid 19122984)
61. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl. 5: S213-56
62. McGuire S. US Department of Agriculture and US Department of Health and Human Services, Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC: US Government Printing Office, 2011 January. Adv Nutr 2011; 2 (3): 293-294
63. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 2001; 107 (2): 256-64 (Pubitemid 32121238)
64. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation 2007; 116 (9): 1032-40 (Pubitemid 47329568)
65. Kwiterovich Jr PO. The role of fiber in the treatment of hypercholesterolemia in children and adolescents. Pediatrics 1995; 96 (5 Pt 2): 1005-9
66. Davidson MH, Dugan LD, Burns JH, et al. A psylliumenriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. Am J Clin Nutr 1996; 63 (1): 96-102 (Pubitemid 26005732)
67. Amundsen AL, Ose L, Nenseter MS, et al. Plant sterol esterenriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr 2002; 76 (2): 338-44 (Pubitemid 34804054)
68. Guardamagna O, Abello F, Baracco V, et al. Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol 2011; 48 (2): 127-33
69. Lichtenstein AH, Deckelbaum RJ. AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels: a statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2001; 103 (8): 1177-9 (Pubitemid 32200197)
70. Tammi A, Ronnemaa T, Miettinen TA, et al. Effects of gender, apolipoprotein E phenotype and cholesterollowering by plant stanol esters in children: the STRIP study. Special Turku Coronary Risk Factor Intervention Project. Acta Paediatr 2002; 91 (11): 1155-62
71. Engler MM, Engler MB, Malloy M, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study. Int J Clin Pharmacol Ther 2004; 42 (12): 672-9 (Pubitemid 39625126)
72. Farpour-Lambert NJ, Aggoun Y, Marchand LM, et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54 (25): 2396-406
73. Tolfrey K, Jones AM, Campbell IG. The effect of aerobic exercise training on the lipid-lipoprotein profile of children and adolescents. Sports Med 2000; 29 (2): 99-112 (Pubitemid 30110382)
74. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis 2009; 205 (1): 23-32
75. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256 (6): 482-90 (Pubitemid 39577582)
76. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267-78
77. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370 (9601): 1781-90 (Pubitemid 350137473)
78. Shafiq N, Bhasin B, Pattanaik S, et al. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Ther 2007; 45 (10): 548-55 (Pubitemid 47527454)
79. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010; (7): CD006401
80. Arambepola C, Farmer AJ, Perera R, et al. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and metaanalysis. Atherosclerosis 2007; 195 (2): 339-47 (Pubitemid 350110336)
81. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27 (8): 1803-10 (Pubitemid 47207177)
82. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116 (6): 664-8 (Pubitemid 47356351)
83. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106 (15): 1943-8 (Pubitemid 35176299)
84. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358 (14): 1431-43 (Pubitemid 351482735)
85. Clauss S, Wai KM, Kavey RE, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 2009; 154 (6): 869-72
86. Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 2009; 22 (6): 487-92
87. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008; 52 (17): 1421-9
88. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89 (3 Pt 2): 525-84
89. Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol 2011; 5 (2): 76-81
90. Manlhiot C, Larsson P, Gurofsky RC, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics 2009; 123 (2): 458-65
91. Wheeler KA, West RJ, Lloyd JK, et al. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985; 60 (1): 34-7 (Pubitemid 15114272)
92. Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993; 92 (1): 78-82 (Pubitemid 23188871)
93. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375 (9719): 998-1006
94. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362 (10): 906-16
95. Karo Bio. Karo Bio terminates the eprotirome program [media release]. 2012 Feb 14 [online]. Available from URL: http://www.karobio.com/investormedia/ pressreleaser/pressrelease?pid=639535 [Accessed 2012 Mar 30]
96. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357 (21): 2109-22 (Pubitemid 350146106)
97. Hudgins LC, Kleinman B, Scheuer A, et al. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102 (9): 1199-204
98. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198 (2): 247-55